CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase I/II Open-Label Dose-Finding Study of Ceritinib Combined With Brentuximab Vedotin for Front-Line Treatment of ALK-Positive Anaplastic Large Cell Lymphoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02729961
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:37:32.961923+00:00
Published At: 2019-10-10T00:00:00+00:00
Record Updated At: 2019-10-10
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Anaplastic Large Cell Lymphoma, ALK-Positive", "CD30-Positive Neoplastic Cells Present", "Systemic Anaplastic Large Cell Lymphoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2019-10-10"
protocolSection.identificationModule.nctId: "NCT02729961"
protocolSection.identificationModule.officialTitle: "A Phase I/II Open-Label Dose-Finding Study of Ceritinib Combined With Brentuximab Vedotin for Front-Line Treatment of ALK-Positive Anaplastic Large Cell Lymphoma"
protocolSection.statusModule.overallStatus: "WITHDRAWN"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.